[Pulmonary thromboembolism and XXXX in the antiphospholipid syndrome--case report].

@entity1 @entity55 @entity1252 @entity5641 @entity2268 @entity1151 @entity1150 @entity262 @entity4555 @entity358 @entity715
INTRODUCTION: @entity1252 is a multisystemic disease of unknown etiology with diverse clinical symptoms depending on the organ affected. Plasma of affected @entity1 contains a specific anticoagulant called @entity4555 . It is an antibody which belongs to the class of antiphospholipid antibodies which bind to phospolipid-binding proteins, molecules of natural coagulation inhibitors, thus increasing the risk of @entity715 . @entity1252 commonly affects the skin, joints, serosa, hematopoietic tissue, kidneys and the nervous system. Pulmonary symptoms may manifest as @entity5641 , @entity55 , chronic @entity358 , but @entity1151 is the most common pulmonary manifestation. CASE REPORT: This is a case report of a young female @entity1 who has been suffering from @entity1252 for twenty years. She was treated for superficial @entity2268 for several times. She was admitted to our hospital a year before, when she developed @entity1151 following @entity1150 of the right leg, although at that time she was treated by oral anticoagulants. She was discharged from hospital with vena cava filter placement and further anticoagulant treatment. In a one year period she was hospitalized again due to @entity1151 . DISCUSSION: @entity715 in @entity1252 are more frequent in patients with antiphospholipid antibodies. Prevention of @entity715 complications by anticoagulant agents in @entity1 who already developed @entity715 manifestations is considered necessary. CONCLUSION: Anticoagulant treatment should be, for preventive reasons, introduced in all @entity1 with a @entity262 and with anticoagulant factor, even if they haven't developed a @entity715 attack and they should undergo prothrombin time measurements and INR: 3-4.
